Name : Human Galectin 9/LGALS9 Protein
Product Source :
Recombinant Human Galectin 9/LGALS9 Protein is expressed from HEK293 with His tag at the N-Terminus. It contains Ala2-Thr323.[Accession | O00182-2]
Molecular Weight :
The protein has a predicted MW of 36.9 kDa. Due to glycosylation, the protein migrates to 50-65 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE
Formulation :
Lyophilized from 0.22μm filtered solution in 20 mM MOPS, 50 mM NaCl, 1 mM EDTA, 2 mM DTT (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human Galectin 9 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Background :
Galectin-9 is a secreted carbohydrate-binding protein with two lectin domains connected by a linker region.Galectins are a family of proteins defined by their binding specificity for β-galactoside sugars, such as N-acetyllactosamine , which can be bound to proteins by either N-linked or O-linked glycosylation..
Synonyms :
Ecalectin; GAL9; gal-9; Galectin9; Galectin-9; HUAT; LGALS9; LGALS9A; MGC117375; MGC125973; MGC125974
References & Citations :
(1)Masaki T , Hirashima M , Niki T , et al. Galectin-9 in Cancer Therapy[J]. Recent Patents on Endocrine Metabolic & Immune Drug Discovery, 2013, 7(2).
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
RANKL/TNFSF11 Protein
SMPDL3A Protein
Popular categories:
Leptin
Complement Component 3b